Whatever Works – Or Might: Pfizer/Wyeth May Keep Both Alzheimer’s Bets
Executive Summary
Sources close to the situation say the merged Pfizer/Wyeth entity will probably maintain ongoing Phase III development programs for both dimebon, the Alzheimer's disease medicine Pfizer in-licensed earlier this year, and bapineuzumab, the antibody being tested by Wyeth and Elan. And the reason has as much to do with the much-bandied "shots on goal" strategy as with efficacy signals exhibited so far by either drug
You may also be interested in...
Alzheimer’s Report To Congress: Faster FDA Approval, Orphan-Like Exclusivity
The development of biomarkers and other steps to speed FDA approval of drugs for Alzheimer's disease was recommended by the Alzheimer's Study Group as part of a 1strategic plan presented to the Senate Select Committee on Aging March 25
Alzheimer’s Report To Congress: Faster FDA Approval, Orphan-Like Exclusivity
The development of biomarkers and other steps to speed FDA approval of drugs for Alzheimer's disease was recommended by the Alzheimer's Study Group as part of a 1strategic plan presented to the Senate Select Committee on Aging March 25
Blinding Them With Science: Genentech Tries To Win Shareholders Over
Genentech's March 2 presentation to analysts and investors - a four hour plus love-in dominated by talk of peptides and pathways - seems to have worked